When compared to traditional synthetic methodologies, the use of biocatalysis for the manufacture of small molecule active pharmaceutical ingredients is increasingly recognized as a more sustainable alternative. Biocatalysis often afford superior product quality, reduced energy needs, low environmental impacts, and access to novel transformations. Despite these promising attributes, biocatalysis is often not considered due to barrier of entry that hamper adoption early in the drug development lifecycle, such as enzyme access, high cost of development, and intellectual property constraints.
In this webinar, we will discuss how these barriers are overcome at Asymchem by sharing some case studies where the benefits of biocatalysis were realized in real-world applications to support drug product development.
Speaker: Xuecheng Jiao, Ph.D.
Director, Center of Biosynthesis Technology,
Asymchem Group

    Fill out the form below to view this presentation